尤瑞克林联合依达拉奉治疗大面积脑梗塞的临床观察

Clinical Observation of Urinary Kallidinogenase Combined With Edaravone in the Treatment of Massive Cerebral Infarction

目的探讨大面积脑梗塞采用尤瑞克林与依达拉奉联合治疗临床效果。方法选取大面积脑梗塞50例,均为我院神经内科2014年5月~2015年5月收治,采用尤瑞克林与依达拉奉联合治疗。结果本组50例大面积脑梗塞患者,基本痊愈25例,占50%;显著进步15例,占30%;进步5例,占10%;无变化5例,占10%,临床总有效率为90%。治疗前神经功能缺损评分为（15.0±4.0）,治疗后为（7.4±2.7）,差异有统计学意义（P〈0.05）。结论大面积脑梗塞采用尤瑞克林与依达拉奉联用治疗,对促神经功能损伤恢复,防范病残效果良好,保障了患者生存质量。

Objective To investigate the clinical curative effect of urinary kallidinogenase combined with edaravone on massive cerebral infarction. Methods 50 cases of massive cerebral infarction patients were selected. They were all admitted to our hospital＇s neurology department,and were treated with urinary kallidinogenase and edaravone. Results There were 25 patients were basically cured,accounting for 50% of the 50 cases of massive cerebral infarction. 15 cases with significant improvements which accounting for 30%. 5 cases improved,accounting for 10%. 5 cases with no changes,accounting for 10%. The overall clinical effective rate was 90%. The neurological deficit score before treatment was（15.0±4.0）,after treatment, it was（7.4±2.7）,the difference was statistically significant（P 0.05）. Conclusion Using urinary kallidinogenase and edaravone in the treatment of massive cerebral infarction,can improve the neurological functional recovery,and its effect on preventing the bad consequences of the disease is good,and the patients＇ quality of survival is ensured.